Effects of rasagiline on freezing of gait in Parkinson's disease - an open-label, multicenter study
Language English Country Czech Republic Media print-electronic
Document type Clinical Trial, Journal Article, Multicenter Study
PubMed
27108605
DOI
10.5507/bp.2016.023
Knihovny.cz E-resources
- Keywords
- Parkinson's disease, Rasagiline, freezing of gait,
- MeSH
- Analysis of Variance MeSH
- Antiparkinson Agents administration & dosage MeSH
- Indans administration & dosage MeSH
- Quality of Life MeSH
- Humans MeSH
- Gait Disorders, Neurologic drug therapy MeSH
- Parkinson Disease drug therapy MeSH
- Surveys and Questionnaires MeSH
- Drug Administration Schedule MeSH
- Aged MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Multicenter Study MeSH
- Names of Substances
- Antiparkinson Agents MeSH
- Indans MeSH
- rasagiline MeSH Browser
AIMS: Freezing of gait is a disabling symptom in advanced Parkinson's disease. Positive effects have been suggested with MAO-B inhibitors. We report on an open label clinical study on the efficacy of rasagiline as add-on therapy on freezing of gait and quality of life in patients with Parkinson's disease. METHODS: Forty two patients with freezing of gait were treated with 1 mg rasagiline daily as an add-on therapy. Patients were assessed at baseline and after 1, 2 and 3 months of treatment. Freezing of gait severity was assessed using the Freezing of Gait Questionnaire, motor impairment by the modified MDS UPDRS part III, and quality of life using the PDQ-39 questionnaire. RESULTS: Patients treated with rasagiline had a statistically significant decrease in FoG-Q score and modified MDS UPDRS score after 1, 2 and 3 months of therapy. A moderately strong (r = 0.686, P = 0.002) correlation between the effects on mobility and freezing of gait was found. We also observed a statistically significant improvement in global QoL and in the subscales mobility, ADL, stigma and bodily discomfort in patients after 3 months of rasagiline therapy. A significant correlation (r = 0.570, P = 0.02) between baseline FoG-Q score and the baseline score for the PDQ Mobility subscale was found. CONCLUSION: In our study rasagiline as add-on antiparkinsonian therapy significantly improved mobility, freezing of gait and quality of life. The positive effect on freezing of gait appears to be related to improvement of mobility.
2nd Department of Neurology Faculty of Medicine Comenius University in Bratislava Slovak Republic
Department of Neurology Hospital Spisska Nova Ves Slovak Republic
Department of Neurology Slovak Health University Roosevelt Hospital Banska Bystrica Slovak Republic
Department of Neurology University Hospital Bratislava Slovak Republic
References provided by Crossref.org
